Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease.
The human papillomavirus (HPV) oncogenes, E6 and E7, are believed to contribute to the development of cervical cancers in women infected with certain HPV genotypes, most notably HPV-16 and HPV-18. Given their expression in tumor tissue, E6 and E7 have been implicated as potential tumor-specific antigens. We have examined an HPV-16 E6- and E7-transgenic mouse lineage for immune responses to these viral oncoproteins. Mice in this lineage express the HPV-16 E6 and E7 genes in their skin and eyes, and on aging, these mice frequently develop squamous cell carcinomas and lenticular tumors. Young transgenic mice, which had measurable E7 protein in the eye but not in the skin, were immunologically naive to E7 protein. They mounted an immune response to E7 on immunization comparable to that of nontransgenic controls, suggesting a lack of immune tolerance to this protein. Older line 19 mice, which are susceptible to skin disease associated with transcription of the E6 and E7 open reading frames, had measurable E7 protein in their skin. These older transgenic mice spontaneously developed antibody responses to endogenous E7 protein, particularly in association with skin disease. Also detected in older mice were delayed-type hypersensitivity responses to E7. These finding parallel the humoral immune response to E7 protein in patients with HPV-associated cervical cancer and suggest that line 19 mice may provide a model for studying the immunobiology of HPV-associated cancers.
Frazer
I H
IH
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison 53706, USA.
Leippe
D M
DM
Dunn
L A
LA
Liem
A
A
Tindle
R W
RW
Fernando
G J
GJ
Phelps
W C
WC
Lambert
P F
PF
D000595:Amino Acid Sequence; D000818:Animals; D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000032:analysis; D005134:Eye Neoplasms / Q000276:immunology / Q000821:virology; D005260:Female; D005814:Genes, Viral; D005838:Genotype; D006801:Humans; D006968:Hypersensitivity, Delayed; D007108:Immune Tolerance; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D009856:Oncogene Proteins, Viral / Q000096:biosynthesis / Q000276:immunology*; D027383:Papillomaviridae / Q000235:genetics* / Q000472:pathogenicity; D050725:Papillomavirus E7 Proteins; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology; D012097:Repressor Proteins; D012871:Skin Diseases / Q000276:immunology* / Q000821:virology; D012878:Skin Neoplasms / Q000276:immunology* / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000821:virology
C068651:E6 protein, Human papillomavirus type 16; D000939:Epitopes; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D010455:Peptides; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16